{"id":"NCT00519285","sponsor":"Sanofi","briefTitle":"Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer","officialTitle":"A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2007-08-22","resultsPosted":"2013-10-10","lastUpdate":"2016-07-22"},"enrollment":1224,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Prostatic Neoplasms","Neoplasm Metastasis"],"interventions":[{"type":"DRUG","name":"Aflibercept","otherNames":["AVE0005","ZALTRAP®)"]},{"type":"DRUG","name":"Placebo (for aflibercept)","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":["Taxotere®"]},{"type":"DRUG","name":"Prednisone or Prednisolone","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Aflibercept","type":"EXPERIMENTAL"}],"summary":"Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC).\n\nThe secondary objectives were:\n\n* To assess the efficacy of aflibercept compared to placebo on other parameters such prostate-specific antigen (PSA) level, cancer related pain, progression free survival (PFS), tumor-based and skeletal events and health-related quality of life (HRQL);\n* To assess the overall safety in both treatment arms;\n* To determine the pharmacokinetics of intravenous (IV) aflibercept in this population;\n* to determine immunogenicity of IV aflibercept.","primaryOutcome":{"measure":"Overall Survival Time","timeFrame":"From randomization up to the cut-off date (median follow-up of 35.4 months)","effectByArm":[{"arm":"Placebo","deltaMin":21.22,"sd":null},{"arm":"Aflibercept","deltaMin":22.14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3802"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":31,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Croatia","Czechia","Denmark","Estonia","France","Germany","Hong Kong","Hungary","Israel","Italy","Netherlands","Poland","Portugal","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["23742877","25515657","24722180"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":184,"n":598},"commonTop":["Alopecia","Fatigue","Diarrhoea","Stomatitis","Nausea"]}}